Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088214 | 0.93 | LMNA (0.48) | LMNAMAPTTHRBNPC1RAB9A | |
| SCHEMBL6606492 | 0.88 | LMNA (0.52) | LMNAMAPTTHRBDRD2MMP13 | |
| SCHEMBL6609494 | 0.86 | LMNA (0.51) | LMNAMAPTTHRBNPC1RAB9A | |
| SCHEMBL6605355 | 0.85 | LMNA (0.51) | LMNAMAPTTHRBNPC1RAB9A | |
| SCHEMBL6607095 | 0.82 | LMNA (0.49) | LMNAMAPTTHRBNPC1RAB9A | |
| SCHEMBL6512442 | 0.82 | LMNA (0.49) | LMNAMAPTTHRBRAB9AALDH1A1 | |
| SCHEMBL6470694 | 0.81 | NPC1 (0.51) | LMNAMAPTTHRBNPC1RAB9A | |
| SCHEMBL6470981 | 0.81 | LMNA (0.47) | LMNAMAPTTHRBSMN1; SMN2TSHR | |
| SCHEMBL6512902 | 0.80 | ALDH1A1 (0.53) | MAPTALDH1A1SMN1; SMN2DRD2TSHR | |
| SCHEMBL6607141 | 0.80 | MMP13 (0.53) | LMNAMAPTTHRBNPC1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368327-B1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1368327-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6656932-B2 | Treating osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure | WARNER-LAMBERT COMPANY | 2003-12-02 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | LMNA 3858/4885MAPT 4336/4885THRB 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.